Laurus Labs Limited vs Zenith Drugs Limited

A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Zenith Drugs Limited (ZENITHDRUG) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Laurus Labs Limited leads LAURUSLABS vs ZENITHDRUG on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability40
  • Growth11
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

ZENITHDRUG takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

125.08
P/E ratio
18.00
19.74
P/B ratio
1.06
0.10%
Dividend yield
1.08%
₹16.47
EPS
₹2.30

Profitability

LAURUSLABS takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.77%
Return on equity
5.38%
17.58%
Return on capital
8.56%
26.09%
EBITDA margin
7.10%
13.07%
Net margin
2.30%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

4.09%
Revenue CAGR (3Y)
14.19%
3.91%
Profit CAGR (3Y)
-7.63%

Size & financial health

LAURUSLABS takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.11L Cr
Market cap
₹70 Cr
₹6,813 Cr
Revenue
₹171 Cr
₹890 Cr
Net profit
₹4 Cr
0.45
Debt / equity
0.75
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 21.00 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
Zenith Drugs Limited
  • + ["Company has delivered good sales growth of 18.9% CAGR over last 5 years", "Stock is trading at 0.95 times its book value"]
  • − []
Laurus Labs Limited full analysis Zenith Drugs Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.